PMID- 26476727
OWN - NLM
STAT- MEDLINE
DCOM- 20160906
LR  - 20221207
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
VI  - 38
IP  - 12
DP  - 2015 Dec
TI  - The impact of vitamin D levels on glycemic control and bone mineral density in 
      postmenopausal women with type 2 diabetes.
PG  - 1365-72
AB  - OBJECTIVES: Whether glycemic control contributes to a decreased number of 
      fractures or favorably impacts bone density in patients with type 2 diabetes 
      mellitus (T2DM)has not been well established. Vitamin D (25 (OH) D3) deficiency 
      appears to be related to glycemic control in patients with T2DM. The aim of this 
      study was to determine the relationship between 25 (OH) D3 levels, glycemic 
      control, bone mineral density (BMD), and the development of osteoporotic 
      fractures (OPF) in postmenopausal women with T2DM. METHODS: We reviewed the 
      charts of 110 postmenopausal women diagnosed with T2DM. Glycosylated hemoglobin 
      A1c (HbA1c) values over the previous 5 years were recorded and an average was 
      obtained. Based on these values,the patients were divided into three groups: 
      optimal,suboptimal, and poor control. Bone mineral density and 25(OH) D3 levels 
      were also recorded. RESULTS: In the group of patients with poorly controlled 
      T2DM, 25 (OH) D3 levels were not significantly lower in comparison with the 
      optimal control group 19.29 +/- 7.70 vs 17.26 +/- 6.93 (p = 0.53). No statistically 
      significant linear relationship between HbA1c and 25 (OH) D3 levels( r(s) = 
      -0.17, p = 0.06) was established. The frequency of osteoporosis and osteopenia 
      was not significantly different between groups. The group with optimal glycemic 
      control had an increased number of OPF events (p = 0.04). CONCLUSIONS: We do not 
      appreciate a significant relationship between 25 (OH) D3 levels and glucose 
      control or OPF. Therefore, more studies are needed to identify the specific 
      effect of 25 (OH) D3 in T2DM physiopathology.
FAU - Perez-Diaz, I
AU  - Perez-Diaz I
FAU - Sebastian-Barajas, G
AU  - Sebastian-Barajas G
FAU - Hernandez-Flores, Z G
AU  - Hernandez-Flores ZG
FAU - Rivera-Moscoso, R
AU  - Rivera-Moscoso R
FAU - Osorio-Landa, H K
AU  - Osorio-Landa HK
FAU - Flores-Rebollar, A
AU  - Flores-Rebollar A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (hemoglobin A1c protein, human)
RN  - P6YZ13C99Q (Calcifediol)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Blood Glucose/*metabolism
MH  - *Bone Density
MH  - Calcifediol/blood/*metabolism
MH  - Diabetes Mellitus, Type 2/blood/*metabolism
MH  - Female
MH  - Glycated Hemoglobin/*metabolism
MH  - Humans
MH  - Middle Aged
MH  - Osteoporotic Fractures/blood/*metabolism
MH  - Postmenopause/blood/*metabolism
MH  - Vitamin D Deficiency/blood/*metabolism
EDAT- 2015/10/20 06:00
MHDA- 2016/09/07 06:00
CRDT- 2015/10/19 06:00
PHST- 2015/01/23 00:00 [received]
PHST- 2015/09/21 00:00 [accepted]
PHST- 2015/10/19 06:00 [entrez]
PHST- 2015/10/20 06:00 [pubmed]
PHST- 2016/09/07 06:00 [medline]
AID - 10.1007/s40618-015-0394-4 [pii]
AID - 10.1007/s40618-015-0394-4 [doi]
PST - ppublish
SO  - J Endocrinol Invest. 2015 Dec;38(12):1365-72. doi: 10.1007/s40618-015-0394-4.